What Is The CONQUER Registry?
In 2018, The SRF launched the CONQUER Registry (an acronym for COllaborative National QUality and Efficacy Registry) – a first-of-it’s-kind nationwide patient registry and biosample repository aimed at improving care and developing more effective, personalized therapies for systemic sclerosis (scleroderma) patients. Scleroderma can manifest in many different ways.
Why is the CONQUER Registry needed?
Some patients have fibrotic skin disease while others do not. Some patients have lung disease, heart disease, or gastrointestinal disease while other patients have many affected organs. Why is this and why is it so difficult for physicians to predict an individual patient’s disease course? Similarly, scleroderma patients need and are treated with many different therapies that span from simply monitoring the disease coupled with symptomatic therapy (e.g. H2 blockers and PPIs for heartburn/reflux) all the way to aggressive therapy aimed at modifying their underlying disease, such as chemotherapeutic immune system resetting with autologous stem cell rescue.
Unfortunately, the answers to critical questions such as these are not fully understood and comprehensive data does not yet exist to allow researchers to evaluate them.
The path to answering these questions requires tracking and collecting data on the health status, disease complications, treatments and outcomes of many patients over many years. The Scleroderma Research Foundation began developing the CONQUER Registry in 2013 with the goal of defining the epidemiology of scleroderma in the current era by enrolling a large group of patients and building a powerful database to track them. Data will be collected over the course of the normal clinic visits – ultimately for thousands of patients over many years. The data generated through the CONQUER Registry will allow researchers to refine disease subsets (going beyond “diffuse” and “limited”) and track patient outcomes for each subset with the aim of enabling more precise and tailored care for individual patients.
About the Program
Due to the rarity of scleroderma, a broad consortium of scleroderma centers is required to enroll a sufficiently large patient population and assemble a sufficiently comprehensive data set to enable deeper insights into the disease. International scleroderma groups have launched large observational studies in Europe, Canada, and Australia; however, these do not necessarily reflect the U.S. scleroderma patient population and, in any case, have some methodological flaws that compromise their utility.
In 2011, the Prospective Registry of Early Systemic Sclerosis (PRESS) registry was developed in the U.S. in response to the FDA’s and the NIH’s calls for attention to Therapeutics for Rare and Neglected Diseases and developing tissue banks linked to clinical outcomes. The PRESS investigators were approached by the Scleroderma Research Foundation (“SRF”) to build upon their efforts. The overarching goal of the partnership of the SRF and the participating academic Scleroderma Centers is to amass the broadest possible cohort of early-stage scleroderma patients. This highly collaborative effort, initially among 12 of the largest scleroderma centers in the U.S., has been named CONQUER (an acronym for COllaborative, National QUality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis (scleroderma) Patients).
The CONQUER Registry became operational in 2019 and aims enroll it’s first 1,000 patients by mid 2022.
It takes a community of dedicated scientists and clinicians to create and carry out a project of this size and scale. The SRF is grateful to the following participating institutions and principal investigators who lend their expertise and leadership to make the CONQUER Registry possible.
|Columbia University||Elana Bernstein, MD, MSc|
|George Washington University||Victoria Shanmugam, MD|
|Georgetown University||Virginia Steen, MD|
|Hospital for Special Surgery||Jessica Gordon, MD|
|Johns Hopkins University||Ami Shah, MD
Laura Hummers, MD
|Mass General Hospital||Flavia Castelino, MD|
|Medical University of South Carolina||Faye Hant, DO, MSCR|
|Northwestern University||Chase Correia, MD|
|Stanford University||Lori Chung, MD, MS|
|University of Michigan||Dinesh Khanna, MD|
|University of Pennsylvania||Nora Sandorfi, MD|
|The University of Texas Health Science Center at Houston||Shervin Assassi, MD|
|University of Utah||Tracy Frech, MD|
The CONQUER Registry will enable researchers to:
- Determine whether certain disease features are associated with or predict clinical and patient-reported outcomes (short-term and long-term).
- Identify which patients require early and aggressive intervention and which patients are better suited for “watchful waiting
- Evaluate the response in the real world (as opposed to the controlled and constrained setting of a clinical trial) to therapeutic agents and to combinations of therapeutic agents.
- Drive more personalized and effective therapy for patients
- Develop insights into drug toxicities that are unique to scleroderma patients (e.g. underlying heart disease due to pulmonary vascular disease)
- Better understand patient satisfaction/issues with the current Standard of Care
- Collect biosamples for future analyses (e.g. genetic factors contributing to disease)
- Establish and support a collaborative network for U.S. scleroderma investigators
- Support the critical infrastructure for future scleroderma studies, including trials for novel therapeutics
How The CONQUER Registry Works
As the founder of the CONQUER Registry, the SRF plays a lead role in the administration and financing of its activities. We are fortunate to have the support of generous corporate sponsors who provide financial resources and expertise to ensure the success of the CONQUER Registry. We gratefully acknowledge these corporate partners, and welcome new partners to join us: